Predicting Survival in Non-Hodgkin's Lymphoma
Author Information
Author(s): A. Costal, R. Silvestrini, R. Giardini, G. Messina-Gabrielli, P. Boracchi, S. Veneroni
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Hypothesis
Can the 3H-thymidine labelling index and flow cytometric S-phase predict survival in patients with non-Hodgkin's lymphoma?
Conclusion
The study found that both the 3H-thymidine labelling index and flow cytometric S-phase are significant indicators of survival in non-Hodgkin's lymphoma patients.
Supporting Evidence
- 3H-thymidine labelling index is an indicator of long-term clinical outcome.
- Flow cytometric S-phase is a discriminant of clinical outcome in NHL patients.
- Simultaneous use of both methods identifies patient groups with different survival better than either method alone.
Takeaway
Doctors can use special tests to see how fast cancer cells are growing, which helps them understand how long patients might live.
Methodology
The study analyzed biopsies from 190 patients, measuring cell growth rates using two different methods on the same samples.
Limitations
The study's findings may not apply to all patients due to the heterogeneity of the patient population and varying treatment approaches.
Participant Demographics
Patients with non-Hodgkin's lymphoma from the National Cancer Institute of Milan, aged under and over 60 years.
Statistical Information
P-Value
0.001
Confidence Interval
1.67-3.39
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website